Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi

İlkay Bahçeci; Soner Yıldız; Yunus Emre İbik; Ömer Faruk Duran; Nuray Arslan; Kazım Şahin

Research Article

Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi

Year 2022, Volume: 7 Issue: 3, 51 - 57, 30.11.2022

İlkay Bahçeci Soner Yıldız Yunus Emre İbik Ömer Faruk Duran Nuray Arslan Kazım Şahin

Abstract

Amaç: Çin’in Wuhan eyaletinde 2019 yılında ortaya çıkıp kısa sürede tüm dünyaya yayılan SARS-CoV-2; Coronaviridae ailesine ait pozitif polariteli, zarflı bir RNA virüsü olup Covid-19 hastalığının etkenidir. Primer olarak akciğer tutulumu ile seyreden bu hastalığın karaciğer başta olmak üzere pek çok sistemi tutabildiği gösterilmiştir. Pandeminin etkisini azaltmak için alınan önlemler hepatit gibi kronik hastalıkların takip ve tedavisinde aksamalara sebep olmuştur. Bu çalışmada hastanemize başvuran ve Covid-19 tanısı doğrulanmış poliklinik, servis ve yoğun bakım birimlerinde takipli hastaların HBsAg, Anti-HCV ve Anti-HIV parametreleri ile mortalite oranları incelenmiştir.

Yöntem: SARS-CoV-2 PCR testi ile tanıları doğrulanmış hastaların HbsAg, Anti-HCV ve Anti-HIV verileri hastane bilgi sisteminden retrospektif olarak elde edilmiştir.

Bulgular: Çalışmaya dahil edilen 352(%47)’si erkek 397(%53)‘si kadın olmak üzere 749 hasta bulunmaktadır. Hastalar sağ kalıma göre iki gruba ayrılmış olup mortal seyreden grubun(n=144) yaş ortalaması sağ kalan gruba(n=605) göre daha yüksek bulunmuş ve istatistiksel olarak anlamlı bir fark saptanmıştır (p<0.001). HBsAg ve Anti-HCV sonuçları reaktif olan hasta gruplarındaki mortalite oranlarına bakıldığında istatistiksel olarak anlamlı bir fark saptanmamıştır (sırasıyla p=0.59, p=0.13). Hastalar takip edildikleri birimlere göre poliklinik(n=265), servis(n=357) ve yoğun bakım(n=127) olmak üzere üç alt gruba ayrılmıştır. Yoğun bakımda takip edilen hastaların mortalite oranı daha yüksek olup istatistiksel olarak anlamlı bulunmuştur (p<0.001).

Sonuç: Pandeminin toplum sağlığına olan primer etkilerinin yanı sıra kronik hastalıkların takip ve tedavisine de olumsuz etkileri olduğu ve bu konuda çalışmalar yapılarak literatüre katkı sağlanması

gerektiğini düşünmekteyiz.

Keywords

Covid-19, ELISA, Hepatit

Supporting Institution

Thanks

References

1. Bahceci I, Senol SS. Post-vaccination COVID-19 positivity and clinical situation analysis in healthcare professionals. Annals of Clinical and Analytical Medicine. 2022; Online puplication; 1-4
2. TanW, Zhao X, Ma X, Wang W, Niu P, Wenbo Xu, et al. A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020. China CDC Wkly. 2020;2(4):61–4.
3. Şenol FF, Bahçeci İ, Arslan N, Aytaç Ö, Öner P, et al.. Comparison of respiratory tract pathogens and antibiotic susceptibility profiles of patients diagnosed with COVID-19 with pre-COVID-19. J Health Sci Med 2022; 5(2): 510-516.
4. Batcik OE., Kanat A., Cankay TU, Ozturk A, Kazancıoglu, L, Kazdal H. et al. COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication. Clinical neurology and neurosurgery. 2021, 106495.
5. Yildiz IE, Bahceci I, Bagın U, Gurlek B, Duran OF, Kostakoglu U, et al.COVID-19 infection in pregnancy: A single-center experience in Rize in the Eastern Black Sea Region. Annals of Clinical and Analytical Medicine. 2022;13(2):141-145
6. Bahceci I, Yildiz IE, Duran OF, Soztanaci US, Kirdi Harbawi Z, Senol FF, et al. Secondary Bacterial Infection Rates Among Patients With COVID-19. Cureus. 2022;14(2):4–11.
7. WHO Coronavirus (COVİD-19) Dashboard [Internet]. [cited 2022 Apr 12]. Available from: https://covid19.who.int/
8. Özen NS, Saraç S, Koyuncu M. COVID-19 Vakalarının Makine Öğrenmesi Algoritmaları ile Tahmini: Amerika Birleşik Devletleri Örneği. Avrupa Bilim ve Teknoloji Dergisi. 2021; (22): 134-139.
9. İskender G. COVID-19 Pandemisinin Kronik Viral Hepatit Hizmetleri Üzerindeki Etkisi. Kesit Akademi Dergisi. 2020; 6(25),685-693.
10. Tekin S, Sümer Ş, Demirtürk N, Aygen B. Chronic hepatitis c in the pandemic. Klimik Derg. 2021;34(1):13–7.
11. Aslan G, Yapıcı G. Infectious Diseases Neglected During the Pandemic. Türk Mikrobiyoloji Cemiyeti Derg. 2021;51(3).
12. Senol FF, Bahceci I, Arslan N, Aytac O, Oner P, Senol A, et al.Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus.Journal of Immunology and Clinical Microbiology.2021; 90-96.
13. Dilek AR., Sahin K., Bahceci I, Dilek, N. The different distribution of hepatitis C virus genotypes in Eastern Black Sea region of Turkey.J Microb Biochem Technol.2013;5(4), 92-4.
14. Yıldız İE, Bahçeci İ, Yılmaz Yavuz A, Kostakoğlu U, Ertürk A. Assessment of Stigma Exposure Status of Patients with Hepatitis B Infection. Viral Hepat J. 2021;27:80-88.
15. Yıldız İE, Bahçeci İ, Ilgar T, Beyazal M, Kostakoğlu U, Ertürk A. Is Liver Biopsy Necessary in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase Level?. Viral Hepatitis Journal. 2022;28(1):1-6.
16. Özen M. Hepatit B Taşıyıcıların Hastalık Hakkındaki Bilgi, Düşünce ve Tutumları. STED / Sürekli Tıp Eğitimi Derg. 2019;28(0000):361–71.
17. WHO. Global Hepatitis Report 2017. Geneva: World Health Organization [Internet]. 2017. Available from: https://www.who.int/publications/i/item/9789241565455
18. Geyik MF. Hepatit B Enfeksiyonu ve Korunma. Konuralp Tıp Derg. 2012;2012(2):54–8.
19. Şenol FF, Bahçeci İ, Algül S. Association of IgE elevation with blood group in COVID-19 patients. Journal of Health Sciences and Medicine. 2022; 5(4): 1092-1096.
20. Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology. 2020;72(3):807–17.
21. Karakoç ZÇ, Pınarbaşı-Şimşek B, Asil R, Dodurgalı R, Çalışkaner F, Özsarı A, et al. First wave in COVID-19 pandemic: A single center experience. Klimik Derg. 2020;33(3):223–9.
22. Alay M. Fen Bilimleri Enstitüsü Patnos Devlet Hastanesi’ne Başvuran Hastalarda HBsAg , anti HCV , HIV Ag / Ab ve anti HBs Seropozitifliğinin Araştırılması. 2019; https://acikbilim.yok.gov.tr/ handle/20.500.12812/622477
23. Barut HŞ, Günal Ö. Dünyada ve Ülkemizde Hepatit C Epidemiyolojisi. Klimik Derg. 2009;22(2):38–43.
24. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: A fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020–6.
25. Şahiner F, Gümral R. Hepatit C İnfeksiyonlarının Laboratuvar Tanısı, Karşılaşılan Güçlükler ve Güncel Tanı Algoritması. Flora J Infect Dis Clin Microbiol. 2020;25(2):139–53.
26. Ronderos D, Omar AMS, Abbas H, Makker J, Baiomi A, Sun H, et al. Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality. World J Clin Cases. 2021;9(29):8749–62.
27. Bahceci I, Yildiz IE. HIV Seropositivity in Patients Admitted to Our Hospital: Six Year Evaluation.Düzce Tıp Fak Derg, 2021;23(1):25-29.
28. Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, et al. Hospitalized Patients with COVID-19 and Human Immunodeficiency Virus: A Case Series. Clin Infect Dis. 2020;71(8):2021–2.
29. Altuntas AO, Karaosmanoglu KH, Yasar KK. HIV/SARS-CoV-2 coinfected patients in Istanbul, Turkey. J Med Virol 2020;92(11):2288-90.

Evaluation of HBsAg, Anti-HCV and Anti-HIV Reactivity in Covid-19 Patients

Year 2022, Volume: 7 Issue: 3, 51 - 57, 30.11.2022

İlkay Bahçeci Soner Yıldız Yunus Emre İbik Ömer Faruk Duran Nuray Arslan Kazım Şahin

Abstract

Objective:MethodsMethods2 emerged in China’s Wuhan province in 2019 and spread allover the world in a short period of time. It is a positive-sense, enveloped RNA virus that belong to the Coronaviridae family and is the causative agent of Covid-19 disease. It primarily represents with pulmonary manifestations, but it can affect many systems, especially the liver. Measures taken to educethe impact of the pandemic caused disruptions in the follow-up and treatment of chronic diseases such as hepatitis. In this study, HBsAg, Anti-HCV and Anti-HIV parameters and mortality rates of patients with confirmed Covid-19 diagnosis admitted to our hospital and followed up in out patient clinics, services and intensive care units were investigated.

Methods: HBsAg, Anti-HCV and Anti-HIV data of patients whose diagnoses were confirmed by SARS-CoV-2 PCR test were obtained retrospectively from the hospitalin formation system.

Results: There were 749 patients included in the study, 352 (47%) male and 397 (53%) female. The patients were divided into two groups according to survival. The meanage of the mortal group (n=144) was found to be higher than the survivor group (n=605) with a statistically significant difference (p<0.001). When the mortality rates in the patient groups with reactive HBsAg and Anti-HCV results were examined, no statistically significan tdifference was found (p=0.59, p=0.13, respectively). The patients were divided into three sub groups according to the units theywerefollowed, as outpatientclinic (n=265), services (n=357) andintensivecareunit (n=127). The mortality rate of the patients followed in the intensive care unit was higher and
statistically significant (p<0.001).

Conclusion: We think that, in addition to the primary effects of the pandemic on public health, it also has negative effects on the follow-up and treatment of chronic diseases and it is necessary to contribute to theliterature by conductings tudies on this subject.Objective

Keywords

Covid-19, ELISA, Hepatis

References

1. Bahceci I, Senol SS. Post-vaccination COVID-19 positivity and clinical situation analysis in healthcare professionals. Annals of Clinical and Analytical Medicine. 2022; Online puplication; 1-4
2. TanW, Zhao X, Ma X, Wang W, Niu P, Wenbo Xu, et al. A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020. China CDC Wkly. 2020;2(4):61–4.
3. Şenol FF, Bahçeci İ, Arslan N, Aytaç Ö, Öner P, et al.. Comparison of respiratory tract pathogens and antibiotic susceptibility profiles of patients diagnosed with COVID-19 with pre-COVID-19. J Health Sci Med 2022; 5(2): 510-516.
4. Batcik OE., Kanat A., Cankay TU, Ozturk A, Kazancıoglu, L, Kazdal H. et al. COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: A short communication. Clinical neurology and neurosurgery. 2021, 106495.
5. Yildiz IE, Bahceci I, Bagın U, Gurlek B, Duran OF, Kostakoglu U, et al.COVID-19 infection in pregnancy: A single-center experience in Rize in the Eastern Black Sea Region. Annals of Clinical and Analytical Medicine. 2022;13(2):141-145
6. Bahceci I, Yildiz IE, Duran OF, Soztanaci US, Kirdi Harbawi Z, Senol FF, et al. Secondary Bacterial Infection Rates Among Patients With COVID-19. Cureus. 2022;14(2):4–11.
7. WHO Coronavirus (COVİD-19) Dashboard [Internet]. [cited 2022 Apr 12]. Available from: https://covid19.who.int/
8. Özen NS, Saraç S, Koyuncu M. COVID-19 Vakalarının Makine Öğrenmesi Algoritmaları ile Tahmini: Amerika Birleşik Devletleri Örneği. Avrupa Bilim ve Teknoloji Dergisi. 2021; (22): 134-139.
9. İskender G. COVID-19 Pandemisinin Kronik Viral Hepatit Hizmetleri Üzerindeki Etkisi. Kesit Akademi Dergisi. 2020; 6(25),685-693.
10. Tekin S, Sümer Ş, Demirtürk N, Aygen B. Chronic hepatitis c in the pandemic. Klimik Derg. 2021;34(1):13–7.
11. Aslan G, Yapıcı G. Infectious Diseases Neglected During the Pandemic. Türk Mikrobiyoloji Cemiyeti Derg. 2021;51(3).
12. Senol FF, Bahceci I, Arslan N, Aytac O, Oner P, Senol A, et al.Investigation of Anti-HBs, HBsAg Positivity in Patients Infected with Hepatitis C Virus.Journal of Immunology and Clinical Microbiology.2021; 90-96.
13. Dilek AR., Sahin K., Bahceci I, Dilek, N. The different distribution of hepatitis C virus genotypes in Eastern Black Sea region of Turkey.J Microb Biochem Technol.2013;5(4), 92-4.
14. Yıldız İE, Bahçeci İ, Yılmaz Yavuz A, Kostakoğlu U, Ertürk A. Assessment of Stigma Exposure Status of Patients with Hepatitis B Infection. Viral Hepat J. 2021;27:80-88.
15. Yıldız İE, Bahçeci İ, Ilgar T, Beyazal M, Kostakoğlu U, Ertürk A. Is Liver Biopsy Necessary in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase Level?. Viral Hepatitis Journal. 2022;28(1):1-6.
16. Özen M. Hepatit B Taşıyıcıların Hastalık Hakkındaki Bilgi, Düşünce ve Tutumları. STED / Sürekli Tıp Eğitimi Derg. 2019;28(0000):361–71.
17. WHO. Global Hepatitis Report 2017. Geneva: World Health Organization [Internet]. 2017. Available from: https://www.who.int/publications/i/item/9789241565455
18. Geyik MF. Hepatit B Enfeksiyonu ve Korunma. Konuralp Tıp Derg. 2012;2012(2):54–8.
19. Şenol FF, Bahçeci İ, Algül S. Association of IgE elevation with blood group in COVID-19 patients. Journal of Health Sciences and Medicine. 2022; 5(4): 1092-1096.
20. Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. Hepatology. 2020;72(3):807–17.
21. Karakoç ZÇ, Pınarbaşı-Şimşek B, Asil R, Dodurgalı R, Çalışkaner F, Özsarı A, et al. First wave in COVID-19 pandemic: A single center experience. Klimik Derg. 2020;33(3):223–9.
22. Alay M. Fen Bilimleri Enstitüsü Patnos Devlet Hastanesi’ne Başvuran Hastalarda HBsAg , anti HCV , HIV Ag / Ab ve anti HBs Seropozitifliğinin Araştırılması. 2019; https://acikbilim.yok.gov.tr/ handle/20.500.12812/622477
23. Barut HŞ, Günal Ö. Dünyada ve Ülkemizde Hepatit C Epidemiyolojisi. Klimik Derg. 2009;22(2):38–43.
24. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: A fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020–6.
25. Şahiner F, Gümral R. Hepatit C İnfeksiyonlarının Laboratuvar Tanısı, Karşılaşılan Güçlükler ve Güncel Tanı Algoritması. Flora J Infect Dis Clin Microbiol. 2020;25(2):139–53.
26. Ronderos D, Omar AMS, Abbas H, Makker J, Baiomi A, Sun H, et al. Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality. World J Clin Cases. 2021;9(29):8749–62.
27. Bahceci I, Yildiz IE. HIV Seropositivity in Patients Admitted to Our Hospital: Six Year Evaluation.Düzce Tıp Fak Derg, 2021;23(1):25-29.
28. Childs K, Post FA, Norcross C, Ottaway Z, Hamlyn E, Quinn K, et al. Hospitalized Patients with COVID-19 and Human Immunodeficiency Virus: A Case Series. Clin Infect Dis. 2020;71(8):2021–2.
29. Altuntas AO, Karaosmanoglu KH, Yasar KK. HIV/SARS-CoV-2 coinfected patients in Istanbul, Turkey. J Med Virol 2020;92(11):2288-90.

There are 29 citations in total.

Details

Primary Language	Turkish
Subjects	Internal Diseases
Journal Section	Research Articles
Authors	İlkay Bahçeci 0000-0003-3662-1629 Soner Yıldız 0000-0002-7587-359X Yunus Emre İbik 0000-0002-6298-6181 Ömer Faruk Duran 0000-0003-1936-128X Nuray Arslan 0000-0002-5893-1452 Kazım Şahin 0000-0002-6459-1853
Publication Date	November 30, 2022
Published in Issue	Year 2022 Volume: 7 Issue: 3

Cite

APA	Bahçeci, İ., Yıldız, S., İbik, Y. E., Duran, Ö. F., et al. (2022). Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi. Journal of Immunology and Clinical Microbiology, 7(3), 51-57.
AMA	Bahçeci İ, Yıldız S, İbik YE, Duran ÖF, Arslan N, Şahin K. Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi. J Immunol Clin Microbiol. November 2022;7(3):51-57.
Chicago	Bahçeci, İlkay, Soner Yıldız, Yunus Emre İbik, Ömer Faruk Duran, Nuray Arslan, and Kazım Şahin. “Covid-19 Hastalarında HBsAg, Anti-HCV Ve Anti-HIV Reaktifliklerinin Değerlendirilmesi”. Journal of Immunology and Clinical Microbiology 7, no. 3 (November 2022): 51-57.
EndNote	Bahçeci İ, Yıldız S, İbik YE, Duran ÖF, Arslan N, Şahin K (November 1, 2022) Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi. Journal of Immunology and Clinical Microbiology 7 3 51–57.
IEEE	İ. Bahçeci, S. Yıldız, Y. E. İbik, Ö. F. Duran, N. Arslan, and K. Şahin, “Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi”, J Immunol Clin Microbiol, vol. 7, no. 3, pp. 51–57, 2022.
ISNAD	Bahçeci, İlkay et al. “Covid-19 Hastalarında HBsAg, Anti-HCV Ve Anti-HIV Reaktifliklerinin Değerlendirilmesi”. Journal of Immunology and Clinical Microbiology 7/3 (November 2022), 51-57.
JAMA	Bahçeci İ, Yıldız S, İbik YE, Duran ÖF, Arslan N, Şahin K. Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi. J Immunol Clin Microbiol. 2022;7:51–57.
MLA	Bahçeci, İlkay et al. “Covid-19 Hastalarında HBsAg, Anti-HCV Ve Anti-HIV Reaktifliklerinin Değerlendirilmesi”. Journal of Immunology and Clinical Microbiology, vol. 7, no. 3, 2022, pp. 51-57.
Vancouver	Bahçeci İ, Yıldız S, İbik YE, Duran ÖF, Arslan N, Şahin K. Covid-19 Hastalarında HBsAg, Anti-HCV ve Anti-HIV Reaktifliklerinin Değerlendirilmesi. J Immunol Clin Microbiol. 2022;7(3):51-7.

Download Cover Image

Article Files

Full Text

Creative Commons Attribution Non-Commercial License: The articles in the Journal of Immunology and Clinical Microbiology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

JICM is a product of QMEL® medicine & publishing